source
- Merck reports positive mid-stage results for Prometheus' tulisokibart in painful skin diseaseMerck presented new data from a mid-stage trial of tulisokibart, a drug acquired through its $10.8 billion purchase of Prometheus Biosciences. The trial evaluated multiple dose levels in patients…
- Trump administration's final Medicare pricing rule limits savings, covering only four firmsThe Trump administration released a final rule intended to lower Medicare prices for drugs administered in physician offices. The rule is part of the Global Benchmark for Efficient Drug Pricing (GL…